Benzinga | Nov 1, 2021 08:19AM EDT

Neurocrine Biosciences Presents New INGREZZA Data At Psych Congress 2021

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) at the 2021 Psych Congress scientific meeting being held October 29--November 1, 2021.

Key highlights include:

* New pooled analysis from the KINECT clinical trial program and long-term extension studies found that long-term use of INGREZZA(r) (valbenazine) led to substantial and clinically meaningful improvements in patients ? 65 years with tardive dyskinesia, some of the first TD-specific vesicular monoamine transporter 2 (VMAT2) inhibitor data for this age group.

* Presentation of the development of the MIND-TD questionnaire, a novel online questionnaire to help facilitate dialogue between healthcare professionals and patients about the risks, symptoms and impact of TD.

* New real-world data from TeleSCOPE, an observational study, showed that the use of telehealth during the COVID-19 pandemic significantly reduced clinicians' abilities to diagnose, assess, monitor and treat drug-induced movement disorders.

* Characterization of the in vitro activity and pharmacokinetic profile of INGREZZA compared to deutetrabenazine confirms a single, specific, potent INGREZZA metabolite with strong VMAT2 affinity and supports once-daily dosing for INGREZZA.

"Presentation of these new data analyses at this year's Psych Congress will continue to help psychiatric healthcare providers further understand the role of INGREZZA in helping people living with tardive dyskinesia," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "These analyses also reflect our continued commitment to provide valuable resources to patients, caregivers and the healthcare community focused on awareness, screening and treatment of tardive dyskinesia."